Singapore, June 26 -- AGC Biologics will commence cell therapy process development and clinical manufacturing services on July 1, 2025, at AGC Inc.'s Yokohama Technical Center (Japan), marking the latest step in the global expansion of the company's Global Cell and Gene Technologies Division.

The improved geographical footprint allows AGC Biologics to better serve customers requiring autologous and allogeneic products across allmarkets,with cell therapy manufacturing now available in three continents (Milan, Italy; Longmont, Colorado, US; Yokohama, Japan).

This new site precedes the opening of anew AGC Biologics Yokohama manufacturing facilityon schedule to be operational in 2027 with pre-clinical through commercial services for mammali...